CORE SERVICES
We offer a small number of high‑impact, board‑level services rather than a long menu of tasks.
Executive education and board briefings
Custom workshops and briefings for leadership teams, non‑executives, and policy stakeholders, grounded in real cases and your own value‑chain data.
We translate complex supply‑chain dynamics into clear strategic choices: where to accept risk, where to build redundancy, and how to align operations with corporate and national resilience goals. Sessions can draw on Dr Angeliki Kotsianti’s board‑level experience chairing benefit‑risk decisions, bringing the medical governance perspective alongside the supply‑chain view.
Typical outcomes: shared language across the board, sharper strategic questions, alignment on investment priorities, and a concrete action list for the next 6–18 months.
Strategic supply‑chain redesign
End‑to‑end mapping and redesign of biopharma value‑chains to reduce variability, compress lead times, and improve resilience across development, clinical, and commercial supply. Dr Angeliki Kotsianti’s CMC and nonclinical development governance background helps ensure redesigns address root causes at the design stage, rather than treating them as downstream regulatory hurdles.
Typical outcomes: clearer footprint strategy, reduced time‑to‑launch, stronger inspection readiness, and more robust contingency plans for single‑source dependencies.
Critical‑medicine resilience reviews
Focused diagnostics on high‑complexity networks (biologics, sterile injectables, cell & gene therapies, radiopharmaceuticals) to identify single points of failure and practical mitigation options. Reviews can incorporate Dr Angeliki Kotsianti’s experience building Pfizer’s global Medically Necessary Products strategy, including the medical criticality classification framework developed for pandemic‑era shortages.
Typical outcomes: prioritised risk register, actionable “no‑regrets” moves, and a roadmap for diversifying CDMO, logistics, and packaging dependencies.
Policy and advanced‑manufacturing advisory
Advice to companies and governments on UK/EU advanced manufacturing supply‑chain bids, cluster strategies, and national resilience programmes. Dr Angeliki Kotsianti co‑led Pfizer’s representation in the EU Critical Medicines Alliance, whose work informed the EU Critical Medicines Act, and brings that regulatory‑policy perspective to engagements.
Typical outcomes: stronger bid narratives, better‑aligned consortia, and policies that reflect how complex biopharma value‑chains actually work.
Expert witness and litigation support
Independent expert opinion and reports for solicitors, insurers, and public inquiries on cases where medicine shortages, supply‑chain failures, or manufacturing and quality defects are alleged to have caused patient harm — including clinical negligence, product liability, and regulatory inquiry matters. Instructions are accepted in compliance with CPR Part 35, with an overriding duty to the court rather than the instructing party.
Typical outcomes: a clear, evidence‑based causation opinion on why a shortage or quality failure occurred, whether it was foreseeable, and what reasonable mitigation should have looked like — delivered in a format ready for court or settlement discussions. On the medical governance and clinical decision‑making side, this service draws on Dr Angeliki Kotsianti’s 19 years at Pfizer holding final medical judgement on recall, reformulation, and supply decisions.
Each engagement is led personally by Hedley Rees, drawing on 40+ years in manufacturing, outsourcing, and policy—and on lessons from sectors like aerospace and semiconductors where failure is not an option. Across all five services, Dr Angeliki Kotsianti contributes the complementary medical governance, regulatory, and clinical‑evidence perspective.
Ready to raise the level of your supply‑chain conversation?
Advising pharma, biotech, CDMOs, cold‑chain and logistics leaders — and their legal counsel — across the UK, EU, and US